Elixir Medical Corporation: EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical's DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)

First head-to-head randomized clinical trial (RCT) of DynamX Bioadaptor compared to Resolute Onyx DES shows statistically significant effectiveness in restoring vessel pulsatility, achieving significantly

Related Keywords

United States ,Milpitas ,California ,Erich Sandoval ,Gewinn Nur ,Motasim Sirhan ,Linkedin ,Twitter ,Elixir Medical Corporation ,Development Of The Dynamx Bioadaptorthe ,Dynamx Bioadaptor ,Resolute Onyx ,Target Lesion Failure ,Drug Eluting Bioadaptor ,Eluting Stent ,Clinical Safety ,Efficacy Results ,Device Effectiveness ,Vessel Function Results ,Plaque Stabilization ,Dynamx Bioadaptorthe ,Elixir Medical ,Dynamx Coronary Bioadaptor System ,Medical Corporation ,Elixir ,Medical ,Corporation ,Uropcr ,023 ,Gate ,Breaking ,Linical ,Data ,Emonstrate ,Ynamx ,Ioadaptor ,Restores ,Vessel ,Lotion ,Junction ,Setter ,Effectiveness ,Months ,Ompared ,Reading ,Drug ,